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combinations include crizotinib/EML4-ALK test in lung cancer; clopidogrel/CYP2C19 
test in cardiovascular disease; natalizumab/ JC virus test in multiple sclerosis; 
maraviroc/HIV tropism test in HIV infection. To define key evidence required by 
health technology assessment (HTA) agencies and payers for reimbursement and 
access decision making, we evaluated global CDx/biomarker test HTAs. Methods: 
HTA Watch conducted a search of global HTA agency websites for HTAs reviewing 
CDx/biomarker tests. HTAs were reviewed for key clinical, economic and other evi-
dence criteria scrutinized or raised as concerns by agencies, and potential impacts/
correlations of such evidence on agency reimbursement recommendations, distin-
guishing between true CDx and non-CDx biomarker tests. Results: CDx/biomarker 
tests reviewed by HTA agencies included those used to inform oncology, cardiovas-
cular or infectious disease, neurological disorder, and allergy/asthma treatments. 
Evidence scrutinized by HTA agencies included demonstration of clinical validity 
and utility versus competing tests or no test, cost-effectiveness and budget impact 
associated with implementing CDx testing, size of the responder population and, for 
solid tumor indications, the practicality of obtaining/availability of sufficient biopsy 
material for biomarker testing. ConClusions: CDx/biomarker tests are necessary 
gatekeepers for informing use of PM drugs, especially in early lines of treatment 
when alternative treatments exist. Since optimal PM market access requires CDx/
biomarker test availability it is critical that the value of CDx/biomarkers is demon-
strated through evidence development that addresses key HTA agency and payer 
needs.
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objeCtives: Severe respiratory infections result in infant hospitalizations for 
LRTI, of which the most common cause is due to respiratory syncytial virus (RSV). 
The economic impact of pediatric hospitalizations for respiratory infections is 
substantial; however the socioeconomic burden it has on parents and caregivers 
is less understood. Methods: Data was attained from the Parent Burden Study: 
A prospective multinational study to determine the humanistic and economic 
burden of infant LRTI hospitalizations during the RSV season. Direct health care 
resource utilization including length of hospitalization stay (LOS) and intensive 
care use (ICU) were obtained from medical chart reviews. Indirect economic 
burden borne by parents were measured in parent surveys administered at the 
time infants were discharged. Lost work productivity was assessed via the Work 
Productivity and Activity Impairment questionnaire, specific to caregivers of chil-
dren hospitalized with respiratory illness. Results: A total of 47 infants (35 term, 
12 preterm), < 1 year of age were included in the Parent Burden Study in Greece. A 
total of 74% of infants had a confirmed diagnosis of RSV. The mean LOS was 7.50 
days (range: 0.66- 40.97, 6.33 days term, 10.91 days preterm). 8.5% (2.9% term and 
25% preterm) required ICU admission and 85.1% had supplemental oxygen and/
or mechanical ventilation support (80% term, 100% preterm). Among fathers, the 
average absenteeism (time away from work) was 19.2%, presenteeism (impaired 
productivity while at work) was 45.6%, and overall work impairment was 55.3%. 
For mothers, the average absenteeism was 47.0%, presenteeism was 35.0% and 
overall work impairment was 54.0%. On average, fathers reported 62.1% activity 
impairment and mothers reported 93.5% due to their child’s hospitalization. A total 
of 51.1% of families required family or arranged childcare to assist siblings during 
the hospitalization. ConClusions: This study demonstrates, in addition to direct 
morbidity burden, infant LRTI hospitalizations have a substantial socioeconomic 
impact on parents and caretakers in Greece.
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objeCtives: Despite evidence of medication adherence benefits, many patients 
do not take their medications as prescribed. The objective of this study was to 
understand asthma medication treatment patterns among asthma patients in the 
US by initial asthma treatment medication. Methods: A retrospective database 
analysis was conducted using Marketscan Commercial and Medicare Supplement 
Data. Patients were identified between January 1, 2005 through March 31, 2011 based 
on asthma related hospitalization, emergency room visit or at least 2 office visits 
at different dates within 1 year. Asthma drug utilization patterns were analyzed 
among patients aged 12 years or older who were initiated on an asthma medica-
tion (without asthma maintenance therapy in the past 12 months) and had at least 
24 months traceable insurance coverage information since their initiation of the 
medication. Results: Among the selected patients (n= 88,567) being followed up 
for 24 months, approximately 30% of patients switched treatments at least once 
regardless of their initial asthma treatment. The three most common medications 
were montelukast sodium (> 90% Singulair), fluticasone propionate and salmeterol 
(Advair) 250/50mcg and 100/50mcg. One prevalent prescription change was to step 
down the steroid component. Patients initiating asthma treatment on combination 
therapy (i.e. Singulair and inhaled corticosteroids) is low (between 0.3% - 1.8%) and 
switch patterns show that over 50% of patients switch to Singulair monotherapy. 
Regardless of their initial treatment and medication switches, on average, asthma 
patients initiate their treatment with 2-3 months days supply; have a gap of over 6 
months (~200days) and switch to another treatment. ConClusions: Our results 
show the high frequency of asthma medication patterns changes. Despite the avail-
to indicators of asthma severity, control, health care utilization and comorbid-
ity. Results: A total of 661 QoL statements were identified from focus group 
transcripts and subsequently used to generate a pool of 112 items in 16 different 
content areas. Psychometric evaluation of field test data yielded a 65-item unidi-
mensional item bank, 4 and 12-item short forms (alpha = .86 and .93, respectively), 
and a simulated computer adaptive test suggesting that as few as 5-items are 
needed to obtain highly precise estimates of the impact of asthma on QoL (IAQL). 
Our measures correlated highly with Marks’ AQLQ and more strongly with the 
PROMIS global physical than mental scale. IAQL was greater in persons with indi-
cators of more severe asthma, less asthma control, and in persons with greater 
health care utilization. ConClusions: The RAND-IAQL item bank is a new freely 
available system for measuring the impact of asthma on Qol that will complement 
other patient-reported outcomes.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is a major health 
problem in India and constitutes an important cause of mortality and morbid-
ity. A cross sectional study was undertaken to assess health related quality of life 
(HRQL) and its determinants in COPD patients from India. Methods: A total of 
126 patients (73.81% male, 26.19% female) recruited using convenient sampling in 
a cross-sectional study. Eligible patients assessed for socioeconomic status, anthro-
pometric measures, COPD severity, dyspnea, and health status using a validated 
Hindi (Regional Language) version of St. George Respiratory Questionnaire (SGRQ). 
Linear regression model was used to examine association between risk factors and 
HRQL with adjustment of age and sex. Results: Mean total score for SGRQ was 
52.66±12.89 showing marked impairment of HRQL. Impairment was associated with 
the severity of airway obstruction but within each GOLD stage the variation (SD) was 
wide [Stage I: 47.8±12.3 (n= 14); Stage II: 49.28±11.69 (n= 47); Stage III: 53.47±11.69 
(n= 44); Stage IV: 61.75±14.14 (n= 21)]. Regression analysis showed that body mass 
index, Forced expiratory volume in 1 minute (FEV1), dyspnea grade and depression 
were associated with poor HRQL. ConClusions: HRQL of COPD patients was sig-
nificantly impaired across all severities. Marked impairment of HRQL was found 
even in patients with milder disease.
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objeCtives: To provide an overview of the first experiences with reassessments 
and appraisals of expensive drugs after 4 years of coverage with evidence devel-
opment (CED) in The Netherlands. Methods: Completed assessments, reas-
sessments and appraisals were summarized. Special attention was paid to the 
consistency of the conclusions at the initial assessment (T= 0) with those at the 
reassessment (T= 4), to the execution of the research proposals, and to the con-
sequences of the reassessments and appraisals. Results: From 2006 until 2012, 
46 T= 0 assessments have been performed: 36 were approved for CED and 10 were 
declined. By mid 2013, the 4 years’ period of CED had ended for 25 drugs. For four 
drugs, T= 4 assessments and appraisals have been completed: omalizumab and 
ranibizumab for treatment of patients with severe asthma and macula degen-
eration respectively; and the orphan drugs alglucosidase alfa and agalsidase for 
treatment of patients with Pompe’s disease and Fabry’s disease. Based on all the 
available evidence, conclusions regarding effectiveness were mostly consistent 
between T= 0 and T= 4 assessments. However, results from the requested outcomes 
research studies between T= 0 and T= 4 were of mixed quality and therefore of lim-
ited relevance for the T= 4 assessment. Nevertheless, most data from the outcomes 
research were useful to evaluate appropriate usage in daily practice and resource 
use. The resource use data was applied in health economic models. In contrast, 
the input for the clinical effectiveness component in the cost-effectiveness assess-
ment was generally derived from pivotal clinical studies already available at T= 0. 
The T= 4 appraisals led to a societal debate on the cost-effectiveness of these 
drugs. The appraisals resulted in pragmatic solutions like a pay-for-performance 
agreement and ongoing price negotiations. ConClusions: Outcomes research as 
part of a CED in The Netherlands has yielded some information regarding the costs 
and appropriate use in daily practice of expensive drugs. The results from these 
CED experiments (or lack thereof) have been used in the subsequent negotiations 
on financial or risk-sharing arrangements.
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objeCtives: Personalized medicines (PM) are the subset of drug therapies whose 
efficacy and/or safety can be predicted or monitored based on the status of specific 
molecular biomarkers. In most cases, access to the applicable biomarker test (also 
called a companion diagnostic (CDx) if the biomarker/test is regulatory approved 
and included in the drug label) is critical for early patient access to the specific 
PM the biomarker status informs. Recent examples of PM and CDx/biomarker test 
